 SAN DIEGO, June 17, 2021 GLOBE NEWSWIRE -- Metacrine, Inc. NASDAQ:MTCR, a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present data at the European Association for the Study of the Liver EASL International Liver CongressTM 2021, being held virtually from June 23-26, 2021. Data to be presented includes results from the Companys Phase 1 trial of MET642, a farnesoid X receptor FXR agonist being developed for the treatment of non-alcoholic steatohepatitis NASH, as well as one oral presentation and one poster focused on preclinical studies examining FXR agonists in rare adult and pediatric cholestatic liver diseases. 